EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Randomisierte kontrollierte StudieOpen Access

ALG ‐020572, an Antisense Oligonucleotide for the Treatment of Chronic Hepatitis B Virus Infection Discontinued for Drug‐Induced Liver Injury

Kosh Agarwal iD, Dan Forton iD, Yoh Zen iD, Min Wu, Tse-I Lin, Kha Le, Sushmita Chanda iD, Lawrence Blatt, John Fry iD, Ed Gane iD

Journal of Viral Hepatitis · 2026

DOI: 10.1111/jvh.70224 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Journal of Viral Hepatitis, 2026. Verfasst von Kosh Agarwal und 9 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Liver Studies, King's College Hospital, London, UK. Hauptthemen laut MEDLINE: Antiviral Agents, Chemical and Drug Induced Liver Injury, Hepatitis B, Chronic, Oligonucleotides, Antisense. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Aligos Therapeutics, Inc..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Current treatment options for chronic HBV infection are suboptimal in that they fail to suppress HBsAg levels. ALG‐020572 is an antisense oligonucleotide designed to reduce viral protein synthesis through degradation of HBV mRNA. ALG‐020572‐401 was a double‐blind, randomized, placebo‐controlled trial consisting of two parts. Part 1 (single‐ascending doses) evaluated the pharmacokinetics, safety and tolerability of single doses of ALG‐020572 or placebo in healthy participants. In Part 2 (multiple dosing), participants with non‐cirrhotic HBeAg‐negative, virologically suppressed chronic HBV infection were administered up to 7 doses of ALG‐020572 to evaluate safety, pharmacokinetics and antiviral activity. In Part 1, 32 participants were randomized to ALG 020572 or placebo. Single doses of ALG‐020572 up to 480 mg were well tolerated. The most common treatment‐emergent adverse event reported was injection site reaction. ALG‐020572 was rapidly absorbed and plasma exposures increased with dose. In Part 2, 8 participants with non‐cirrhotic HBeAg‐negative virologically suppressed chronic hepatitis B infection were enrolled and received up to 7 doses of ALG‐020572. The study was prematurely discontinued after 4 participants experienced significant alanine aminotransferase elevations that were subsequently attributed to drug‐induced liver injury. Single doses of ALG‐020572 demonstrated a favourable pharmacokinetic and safety profile in healthy participants. Unexpectedly, ALG‐020572 was poorly tolerated in participants with chronic HBV infection, resulting in the early termination of the study and further development of ALG‐020572 due to idiosyncratic drug‐induced liver injury, suggesting caution is required in the development of this class of drugs. Trial Registration: Registered at clinicaltrials.gov : NCT0500102

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antiviral AgentsChemical and Drug Induced Liver InjuryHepatitis B, ChronicOligonucleotides, AntisenseAdultFemaleHumansMaleMiddle AgedYoung AdultDouble-Blind MethodHepatitis B virusPlacebosTreatment Outcome

Stichwörter der Autor:innen

HBsAgantisense oligonucleotideschemical and drug‐induced liver injurychronic hepatitis Bhepatitis B virus

Substanzen

Antiviral AgentsOligonucleotides, AntisensePlacebos

Autor:innen und Institutionen

  • Institute of Liver Studies, King's College Hospital, London, UK.
  • NIHR St. George's Clinical Research Facility, St. George's University Hospitals, London, UK.
  • Aligos Therapeutics, Inc., San Francisco, California, USA.
  • Aligos Belgium BV, Mechelen, Belgium.
  • University of Auckland, Auckland, New Zealand.

ORCID-Profile: Kosh Agarwal, Dan Forton, Yoh Zen, Sushmita Chanda, John Fry, Ed Gane

Förderung

  • Aligos Therapeutics, Inc.

Zitieren

APA

Agarwal, K., Forton, D., Zen, Y., Wu, M., Lin, T. I., Le, K., Chanda, S., Blatt, L., Fry, J., & Gane, E. (2026). ALG ‐020572, an Antisense Oligonucleotide for the Treatment of Chronic Hepatitis B Virus Infection Discontinued for Drug‐Induced Liver Injury. Journal of Viral Hepatitis. https://doi.org/10.1111/jvh.70224

Vancouver

Agarwal K, Forton D, Zen Y, Wu M, Lin TI, Le K, et al. ALG ‐020572, an Antisense Oligonucleotide for the Treatment of Chronic Hepatitis B Virus Infection Discontinued for Drug‐Induced Liver Injury. Journal of Viral Hepatitis. 2026. doi:10.1111/jvh.70224

BibTeX
@article{Agarwal2026,
  author = {Agarwal, Kosh and Forton, Dan and Zen, Yoh and Wu, Min and Lin, Tse-I and Le, Kha and Chanda, Sushmita and Blatt, Lawrence and Fry, John and Gane, Ed},
  title = {ALG ‐020572, an Antisense Oligonucleotide for the Treatment of Chronic Hepatitis B Virus Infection Discontinued for Drug‐Induced Liver Injury},
  journal = {Journal of Viral Hepatitis},
  year = {2026},
  doi = {10.1111/jvh.70224}
}
Kostenlos starten →